Skip to main navigation

About
Leadership
The Beaker
Pipeline & Innovation
Diabetes & Obesity
Oncology
Literature References
Clinical Trials
Partnering
Careers & Contact Us
Investors & Media
Menu Menu

LinkedIn
Twitter
Facebook
Instagram
Mail

Corporate Presentations & Information

Corporate Presentations & Information

Investor Menu

Overview
Corporate Presentations
News & Events
- Press Releases
- Events
Financials & Filings
- SEC Filings
- Annual Reports
Governance
Stock Info
- Stock Quote & Chart
- Analyst Coverage
IR Resources

Corporate Presentation

Biomea Fusion Corporate Presentation Q4 2024

Backgrounders

Backgrounders

Backgrounder – Biomea The Company 5.1 MB

Backgrounder - Beta Cells and Their Proliferation Capacity 3.8 MB

Backgrounder - BMF-219 Preclinical and Clinical Results in Oncology 3 MB

Backgrounder - BMF-219's Mechanism of Action in Diabetes and Oncology 3.2 MB

Backgrounder - Clinical Results of BMF-219 in Diabetes 4.4 MB

Backgrounder - Diabetes Current Standard of Care Solutions and Unmet Need 5.4 MB

Backgrounder - Preclinical Results of BMF-219 in Diabetes 3.7 MB

Backgrounder - The Role of Beta Cells in Diabetes 2 MB

Backgrounder - The Role of Menin in Diabetes and Oncology 1.5 MB

Backgrounder - Type 2 Diabetes Subgroup Analysis 1.1 MB

Factsheets

Fact Sheets

Biomea icovamenib in Diabetes 4.1 MB

BMF-500 in AML 3.8 MB

Biomea Overview 4.7 MB

Biomea Corporate Overview and Programs.pdf 360.8 KB

BMF-219 in Diabetes 437.9 KB

BMF-219 in Oncology.pdf 249.4 KB

About Menin 244.7 KB

Investor Contact

admin-home
info
address-book
medkit
flask
briefcase
pressthis
map-signs

linkedin
twitter
facebook
instagram
mail

Copyright 2020-2021 Biomea Fusion, Inc.
All Rights Reserved. Privacy Policy | Terms of Service